Skip to main content

CASE REPORT article

Front. Oncol.
Sec. Cancer Immunity and Immunotherapy
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1402490

Tislelizumab plus Chemotherapy in Metastatic Extramammary Paget Disease after Surgery: A Case Report

Provisionally accepted
Dongxing Wang Dongxing Wang 1Chuang Huang Chuang Huang 1*Wang D. Ming Wang D. Ming 2Dehui Chang Dehui Chang 1*
  • 1 People's Liberation Army Joint Logistics Support Force 940th Hospital, Lanzhou, Gansu Province, China
  • 2 Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, Beijing Municipality, China

The final, formatted version of the article will be published soon.

    Extramammary Paget disease (EMPD) is a rare epithelial adenocarcinoma in apocrine-gland rich skin, involving the vulva, the scrotum, and the penis. with distant metastases and a poor prognosis. Local EMPD patients generally have a good prognosis, with expected 5-year survival of 60%-92%, but distant metastasis represents poor prognosis and 5-year survival of 10%. Treatment approaches for advanced EMPD are chemotherapy and biological agents, which carry limited efficacy. We report the case of a 57-year-old man diagnosed with metastatic EMPD, who showed a long-term disease control with a combination therapy (an immune checkpoint inhibitor -tislelizumab plus chemotherapy -paclitaxel albumin and cisplatin). This patient underwent a wide penile scrotal lesion excision and six cycles of tislelizumab plus chemotherapy. The patient achieved partial response for the metastatic lesions according to the Response Evaluation Criteria in Solid Tumors (version 1.1). This case report supports further investigation of the combination treatment of chemotherapy and immune checkpoint inhibitors in the management of metastatic EMPD, which currently has an abysmal prognosis and no standardized treatment.

    Keywords: Extramammary Paget's disease, Immunotherapy, tislelizumab, chemotherapy, Surgery

    Received: 17 Mar 2024; Accepted: 08 Oct 2024.

    Copyright: © 2024 Wang, Huang, Ming and Chang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Chuang Huang, People's Liberation Army Joint Logistics Support Force 940th Hospital, Lanzhou, Gansu Province, China
    Dehui Chang, People's Liberation Army Joint Logistics Support Force 940th Hospital, Lanzhou, Gansu Province, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.